Small cell lung cancer
- PMID: 12527584
- DOI: 10.1378/chest.123.1_suppl.259s
Small cell lung cancer
Abstract
Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.
Similar articles
-
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2013 May;143(5 Suppl):e400S-e419S. doi: 10.1378/chest.12-2363. Chest. 2013. PMID: 23649448
-
Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).Chest. 2007 Sep;132(3 Suppl):324S-339S. doi: 10.1378/chest.07-1385. Chest. 2007. PMID: 17873178
-
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).Chest. 2007 Sep;132(3 Suppl):314S-323S. doi: 10.1378/chest.07-1384. Chest. 2007. PMID: 17873177 Review.
-
Combined-modality therapy for limited-stage small cell lung cancer.Semin Oncol. 2001 Apr;28(2 Suppl 4):14-22. doi: 10.1053/sonc.2001.25739. Semin Oncol. 2001. PMID: 11479892 Review.
-
Therapy of limited stage small cell lung cancer.Cancer Treat Res. 2001;105:229-52. doi: 10.1007/978-1-4615-1589-0_9. Cancer Treat Res. 2001. PMID: 11224989 Review. No abstract available.
Cited by
-
Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer.Cancers (Basel). 2024 Mar 15;16(6):1165. doi: 10.3390/cancers16061165. Cancers (Basel). 2024. PMID: 38539500 Free PMC article.
-
Drug-tolerant persister cells in cancer: the cutting edges and future directions.Nat Rev Clin Oncol. 2023 Nov;20(11):799-813. doi: 10.1038/s41571-023-00815-5. Epub 2023 Sep 25. Nat Rev Clin Oncol. 2023. PMID: 37749382 Review.
-
Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects.Onco Targets Ther. 2023 Aug 2;16:657-671. doi: 10.2147/OTT.S272552. eCollection 2023. Onco Targets Ther. 2023. PMID: 37551311 Free PMC article. Review.
-
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.Front Pharmacol. 2023 Jul 20;14:1241130. doi: 10.3389/fphar.2023.1241130. eCollection 2023. Front Pharmacol. 2023. PMID: 37547339 Free PMC article.
-
Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.Transl Lung Cancer Res. 2022 May;11(5):832-844. doi: 10.21037/tlcr-22-313. Transl Lung Cancer Res. 2022. PMID: 35693282 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical